ClinicalTrials.gg
RecruitingNCT07848854Updated Sep 30, 2026

Trop2-Targeted NIR-II Fluorescent Probe for Identifying Bladder Cancer in Ex Vivo Bladder Samples

A Phase 2 interventional study of TTP-ICG fluorescent probe in Bladder Cancer (BC) and Urothelial Carcinoma (UC), sponsored by Yunnan Cancer Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Yunnan Cancer Hospital · Phase 2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 194 studies in Urinary Bladder Neoplasms with a site in China — 102 open to participants now, 119 under way, 17 of them phase 3. Urinary Bladder Neoplasms · China.

Planned enrollment
105th of 141
30 · median 75
Started
2026
with 24 others
Phase 2
40 of 194
22 open now
Primary completion
2027-07
later than 62 of 118 live
Registered
191st of 194
by date

Among the 194 studies in Urinary Bladder Neoplasms with a site in China, this one is the 105th largest by planned enrollment of the 141 interventional ones that give a count, is one of 25 that started in 2026, is one of 40 in phase 2, reaches primary completion later than 62 of the 118 other live ones, and was the 191st registered.

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

102 of the 194 studies in Urinary Bladder Neoplasms with a site in China are open now. Recruiting first, the newest first:

96 more — sign in →

All 102 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Urinary Bladder Neoplasms with a site in China, or all of them as a file.
02

Study summary

Up to 30% of non-muscle-invasive bladder cancer (NMIBC) lesions may be missed by standard white-light cystoscopy, resulting in high tumor recurrence rate. This is a single-center, single-arm, phase 2 prospective study. We apply Trop2-targeted NIR-II fluorescent probe TTP-ICG with rapid incubation to ex vivo bladder specimens from patients undergoing radical cystectomy. Near-infrared fluorescence imaging is performed after short-time incubation and washing. Using histopathology as gold standard, we evaluate the sensitivity, specificity of this imaging system for identifying bladder cancer lesions, and analyze correlation between fluorescence intensity and pathological diagnosis. 30 subjects will be enrolled.

Read the detailed description

> Bladder cancer is one of the most common human malignancies. Approximately 70% of newly diagnosed patients present with non-muscle-invasive bladder cancer (NMIBC). White-light endoscopy, the routine clinical method, misses up to 30% of lesions especially small satellite tumors and flat carcinoma in situ (CIS), contributing to high recurrence up to 70%. Existing alternative endoscopic imaging techniques suffer from high false-positive rates or narrow field-of-view. Trop2 is overexpressed in urothelial bladder carcinoma, and Trop2-targeted antibody-drug conjugate has been FDA-approved for urothelial carcinoma, validating Trop2 as a reliable tumor biomarker.

This phase 2, single-center, single-arm prospective study plans to enroll 30 suspected or confirmed bladder tumor patients scheduled for radical cystectomy. After surgical removal of whole-bladder specimen ex vivo, 50 mL TTP-ICG solution (20 μg/mL) is instilled into the lumen of isolated bladder for 3-minute incubation. After discarding probe solution, the bladder lumen is rinsed 3 times with normal saline. Near-infrared-II fluorescence imaging is performed over the entire inner bladder surface. Lesions highlighted by fluorescence are sampled for histopathological examination. With postoperative histopathology as gold standard, we calculate sensitivity, specificity, false-positive rate, false-negative rate of this imaging system for detecting malignant lesions. Fluorescence intensity of tumor foci and normal bladder mucosa are measured to explore correlation between fluorescence signal and pathological diagnosis. This ex-vivo study provides pre-clinical evidence for future in-vivo application, aiming to reduce missed diagnosis and recurrence of NMIBC.

03

Conditions studied

  • Bladder Cancer (BC)
  • Urothelial Carcinoma (UC)

Keywords

  • Bladder Cancer
  • TROP2
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Suspected or confirmed bladder tumor patients who are scheduled to undergo radical cystectomy.
  2. Able to provide written and comply with study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Suffering from other invasive malignant tumors.
  2. With severe comorbidities including congenital malformation, acute active inflammation, cachexia, myocardial infarction or stroke within past 6 months, severe hepatic or renal insufficiency.
  3. Pregnant or lactating female subjects.
  4. Participated in another clinical trial within past 30 days.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    TTP-ICG ex-vivo rapid incubation fluorescence imaging

    Drug: TTP-ICG fluorescent probe

Interventions

  • DrugTTP-ICG fluorescent probe

    After radical cystectomy, 50 mL TTP-ICG solution (20 μg/mL) is instilled into lumen of isolated bladder specimen for 3 minutes incubation. Then probe solution is drained; bladder lumen washed 3 times by normal saline(30 seconds per time). Near-infrared-II fluorescence imaging is performed on inner bladder surface. Fluorescent highlighted lesions are harvested for pathological examination.

06

What researchers measure

Primary outcomes

  1. Diagnostic Sensitivity of ex-vivo Trop2-targeted NIR-II fluorescence imaging for detecting malignant bladder lesions

    Sensitivity of TTP-ICG rapid-incubation NIR-II fluorescence imaging to identify malignant bladder lesions in ex-vivo radical-cystectomy specimens. Histopathology serves as gold-standard reference. Sensitivity = true-positive / (true-positive + false-negative).

    Time frame: Within 7 days after collection of ex-vivo bladder specimen, after histopathology report available

  2. Diagnostic Specificity of ex-vivo Trop2-targeted NIR-II fluorescence imaging for detecting malignant bladder lesions

    Specificity of TTP-ICG rapid-incubation NIR-II fluorescence imaging to identify malignant bladder lesions in ex-vivo radical-cystectomy specimens. Histopathology serves as gold-standard reference. Specificity = true-negative / (true-negative + false-positive)

    Time frame: Within 7 days after collection of ex-vivo bladder specimen, after histopathology report available

  3. False-Positive Rate of ex-vivo Trop2-targeted NIR-II fluorescence imaging for detecting malignant bladder lesions

    False-positive rate of TTP-ICG rapid-incubation NIR-II fluorescence imaging for bladder-cancer lesion detection on ex-vivo specimens, using histopathology as gold standard. False-positive rate = false-positive / (true-negative + false-positive)

    Time frame: Within 7 days after collection of ex-vivo bladder specimen, after histopathology report available

  4. False-Negative Rate of ex-vivo Trop2-targeted NIR-II fluorescence imaging for detecting malignant bladder lesions

    False-negative rate of TTP-ICG rapid-incubation NIR-II fluorescence imaging for bladder-cancer lesion detection on ex-vivo specimens, using histopathology as gold standard. False-negative rate = false-negative / (true-positive + false-negative)

    Time frame: Within 7 days after collection of ex-vivo bladder specimen, after histopathology report available

Secondary outcomes

  1. Near-infrared-II fluorescence intensity of tumor lesions and normal bladder mucosa

    Quantitative NIR-II fluorescence intensity values measured for malignant tumor lesions and normal bladder mucosal epithelium on ex-vivo bladder specimens

    Time frame: Within 7 days after collection of ex-vivo bladder specimen, after histopathology report available

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jul 2027, 11 months after the start.

Of 154 non-industry phase 2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 94. This study's planned 11 months is below that.

Counting every sponsor, half of 193 studies reached it within 52 months; a quarter within 36 and three quarters within 91.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 30, 2026
StartActual
Aug 1, 2026
Primary completionEst.
Jul 30, 2027
CompletionEst.
Aug 30, 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07848854
Lead sponsor
Yunnan Cancer Hospital
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Aug 1, 2026
Primary completion
Jul 30, 2027 (estimated)
Completion
Aug 30, 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Shengjie Lin, Doctor of Medicine
Contact
Linshengjie1128@163.com
86+17850112800

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion